Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C560
http://purl.obolibrary.org/obo/NCIT_C560
|
|---|---|
| Preferred Name | Hydroxyurea |
| Definitions |
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04) |
|---|---|
| prefLabel | Hydroxyurea
|
| label | Hydroxyurea
|
| CHEBI_ID | CHEBI:44423
|
| PDQ_Closed_Trial_Search_ID | 40685
|
| code | C560
|
| Has_Target | |
| prefixIRI | NCIT:C560
|
| in_subset |
See more
See less
|
| Display_Name | Hydroxyurea
|
| Preferred_Name | Hydroxyurea
|
| FDA_UNII_Code | X6Q56QN5QC
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | CH4N2O2
|
| Maps_To | Hydroxyurea
|
| CAS_Registry | 127-07-1
|
| NSC Number | 32065
|
| NCI_Drug_Dictionary_ID | 40685
|
| Legacy Concept Name | Hydroxyurea
|
| type | |
| ALT_DEFINITION | An anticancer drug that belongs to the family of drugs called antimetabolites.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 40685
|
| Accepted_Therapeutic_Use_For | Chronic Myelogenous Leukemia; Head and Neck Cancer; Malignant Melanoma; Ovarian Carcinoma; Sickle Cell Anemia; Adjuvant in Retroviral Therapy.
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0020402
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |